The pharma firm reported a US$1.65 billion loss in Q4 2025, driven by a major write-down and falling Covid-19 product sales.

"Providing clarity around modern statistical methods will help sponsors bring more cures and meaningful treatments to ...

PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent ...

LIBERTY is a Phase 3, randomized, double-blind study to evaluate the safety, serum virus neutralizing antibody responses, and pharmacokinetics of VYD2311, an mRNA COVID vaccine, and co-administered ...

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues. "Current financial guidance does not anticipate any ...

Pfizer (NYSE: PFE) posted fourth-quarter 2025 revenue of about $18 billion, down 1% from the year-ago quarter, and adjusted ...

SK bioscience will advance a novel respiratory syncytial virus (RSV) monoclonal antibody for global health under license from ...

BioNTech (NasdaqGS:BNTX) has appointed Kylie Jimenez as Chief People Officer. The new executive role is designed to support BioNTech's goal of becoming a multi product oncology company by 2030. This ...

The Zacks Medical - Products industry is grappling with a challenging operating environment due to the tariffs imposed by the United States on multiple trading partners, including China, Europe and ...